Strategies for Pancreatic Cancer-Responsive Nanodrug Platforms Targeting Tumor Hypoxic Environments

Abstract Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, largely because of its profoundly hypoxic and desmoplastic tumor microenvironment (TME), which hinders drug delivery and promotes resistance to chemotherapy, radiotherapy, and immunotherapy. Hypoxia not only serves as a therapeutic barrier, but also presents a selective vulnerability that can be exploited by smart nanocarriers. This review highlights recent advances in hypoxia-responsive nanoparticle (NP) platforms designed to overcome these barriers through four key strategies: (1) hypoxia-triggered drug release using bioreductively cleavable linkers and hypoxia-activated prodrugs; (2) surface functionalization with tumor-targeting ligands, such as aptamers and antibodies; (3) selective activation of hypoxia-activated prodrugs that become cytotoxic only under low oxygen conditions; and (4) multi-stimuli-responsive designs integrating pH, enzymatic, or exogenous triggers. Preclinical studies in PDAC models have demonstrated that these systems can achieve over two-fold tumor growth inhibition and a 60% increase in intratumoral necrosis compared with controls, validating their in vivo therapeutic potential. Furthermore, the recent integration of artificial intelligence into NP design has accelerated the optimization of hypoxia-responsive systems by enabling the rapid identification of structure–function relationships and in silico prediction of tumor-specific accumulation. Collectively, these strategies offer a promising route toward more effective, selective, and personalized nanomedicines for pancreatic cancer treatment.

• Publication year

  2025

• Venue

  International Journal of Nanomedicine

• Publication date

  2025-11-01

• Fields of study

  Medicine, Materials Science

• Identifiers
  DOI 10.2147/IJN.S548825PMID 41229675PMCID 12604595
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Preclinical Development of Magnetic Nanoparticles for Hyperthermia Treatment of Pancreatic Cancer.

  2025cited by this paper
• Development of Stimuli-Responsive Polymeric Nanomedicines in Hypoxic Tumors and Their Therapeutic Promise in Oral Cancer

  2025cited by this paper
• Hypoxia-responsive nanoparticles for fluorescence diagnosis and therapy of cancer

  2025cited by this paper
• 2-Nitroimidazole-Functionalized Superparamagnetic Iron Oxide Nanoparticles Detect Hypoxic Regions of Glioblastomas on MRI and Improve Radiotherapy Efficacy

  2025influential reference
• Unveiling the future of cancer stem cell therapy: a narrative exploration of emerging innovations

  2025cited by this paper
• Extracellular matrix stiffness: mechanisms in tumor progression and therapeutic potential in cancer

  2025cited by this paper
• BE-43547A2 exerts hypoxia-selective inhibition on human pancreatic cancer cells through targeting eEF1A1 and disrupting its association with FoxO1

  2025cited by this paper
• Engineered hypoxia-responsive albumin nanoparticles mediating mitophagy regulation for cancer therapy

  2025influential reference
• Hypoxia-Responsive Nanomicelle Based on 2-Nitroimidazole for Tumor Treatment Through Chemotherapy and Modulation of the Tumor Redox Microenvironment

  2024cited by this paper
• pH-responsive targeted nanoparticles release ERK-inhibitor in the hypoxic zone and sensitize free gemcitabine in mutant K-Ras-addicted pancreatic cancer cells and mouse model.

  2024cited by this paper
• Targeted Nanoparticle-Based Diagnostic and Treatment Options for Pancreatic Cancer

  2024cited by this paper
• High hypoxia status in pancreatic cancer is associated with multiple hallmarks of an immunosuppressive tumor microenvironment

  2024cited by this paper
• Hypoxia and Singlet Oxygen Dual-Responsive Micelles for Photodynamic and Chemotherapy Therapy Featured with Enhanced Cellular Uptake and Triggered Cargo Delivery

  2024cited by this paper
• Modelling and breaking down the biophysical barriers to drug delivery in pancreatic cancer.

  2024cited by this paper
• Development of an AI model for predicting hypoxia status and prognosis in non-small cell lung cancer using multi-modal data

  2024cited by this paper
• Investigating the effects of stereotactic body radiation therapy on pancreatic tumor hypoxia and microvasculature in an orthotopic mouse model using intravital fluorescence microscopy

  2024cited by this paper
• Hypoxia-Inducible Factor 1-Alpha (HIF-1α) and Cancer: Mechanisms of Tumor Hypoxia and Therapeutic Targeting

  2024cited by this paper
• Targeting Hypoxia-Inducible Factor-1α in Pancreatic Cancer: siRNA Delivery Using Hyaluronic Acid-Displaying Nanoparticles

  2024cited by this paper
• Charge-Reversal Nano-Drug Delivery Systems in the Tumor Microenvironment: Mechanisms, Challenges, and Therapeutic Applications

  2024influential reference
• Machine learning-guided high throughput nanoparticle design

  2024cited by this paper
• Carbonic anhydrase IX: An atypical target for innovative therapies in cancer.

  2024cited by this paper
• Dual hypoxia-responsive supramolecular complex for cancer target therapy

  2023influential reference
• Hypoxia-Responsive Polymeric Nanoprodrugs for Combo Photodynamic and Chemotherapy

  2023cited by this paper
• Alteration in the expression of the chemotherapy resistance‑related genes in response to chronic and acute hypoxia in pancreatic cancer

  2023cited by this paper
• Artificial intelligence enhanced sensors - enabling technologies to next-generation healthcare and biomedical platform

  2023cited by this paper
• Hypoxia-elicited Exosomes Promote the Chemoresistance of Pancreatic Cancer Cells by Transferring LncROR via Hippo Signaling

  2023cited by this paper
• Overcoming the Fibrotic Fortress in Pancreatic Ductal Adenocarcinoma: Challenges and Opportunities

  2023cited by this paper
• Correlation between hypoxia and HGF/c-MET expression in the management of pancreatic cancer.

  2023cited by this paper
• Hypoxia, a Targetable Culprit to Counter Pancreatic Cancer Resistance to Therapy

  2023cited by this paper
• Quiescent Cancer Cells—A Potential Therapeutic Target to Overcome Tumor Resistance and Relapse

  2023cited by this paper
• Cancer-associated fibroblasts: The chief architect in the tumor microenvironment

  2023cited by this paper
• Cancer statistics, 2023

  2023cited by this paper
• Nanoparticles and convergence of artificial intelligence for targeted drug delivery for cancer therapy: Current progress and challenges

  2023cited by this paper
• Dual-responsive disassembly of core-shell nanoparticles with self-supplied H2O2 and autocatalytic Fenton reaction for enhanced chemodynamic therapy

  2022influential reference
• Smart hypoxia-responsive transformable and charge-reversible nanoparticles for the deep penetration and tumor microenvironment modulation of pancreatic cancer.

  2022cited by this paper
• Hypoxia promotes an inflammatory phenotype of fibroblasts in pancreatic cancer

  2022cited by this paper
• Hypoxia-Inducible Factor-1: A Novel Therapeutic Target for the Management of Cancer, Drug Resistance, and Cancer-Related Pain

  2022cited by this paper
• Predicting Nanoparticle Delivery to Tumors Using Machine Learning and Artificial Intelligence Approaches

  2022cited by this paper
• PEGPH20, a PEGylated human hyaluronidase, induces radiosensitization by reoxygenation in pancreatic cancer xenografts. A molecular imaging study

  2022cited by this paper
• Cancer-associated fibroblasts in pancreatic ductal adenocarcinoma

  2022cited by this paper
• Nanoparticle-Based Therapeutic Strategies for Enhanced Pancreatic Ductal Adenocarcinoma Immunotherapy

  2022cited by this paper
• Hypoxia-Activated PEGylated Paclitaxel Prodrug Nanoparticles for Potentiated Chemotherapy.

  2022cited by this paper
• Dual‐Cascade Responsive Nanoparticles Enhance Pancreatic Cancer Therapy by Eliminating Tumor‐Resident Intracellular Bacteria

  2022influential reference
• The Extracellular Matrix: A Key Accomplice of Cancer Stem Cell Migration, Metastasis Formation, and Drug Resistance in PDAC

  2022cited by this paper
• Interfering with Tumor Hypoxia for Radiotherapy Optimization

  2021cited by this paper
• Overcoming the Tumor Microenvironmental Barriers of Pancreatic Ductal Adenocarcinomas for Achieving Better Treatment Outcomes

  2021cited by this paper
• Immune Regulation in Time and Space: The Role of Local- and Long-Range Genomic Interactions in Regulating Immune Responses

  2021cited by this paper
• Extracellular matrix and its therapeutic potential for cancer treatment

  2021cited by this paper
• VHH212 nanobody targeting the hypoxia-inducible factor 1α suppresses angiogenesis and potentiates gemcitabine therapy in pancreatic cancer in vivo

  2021cited by this paper
• Harnessing metabolic dependencies in pancreatic cancers

  2021cited by this paper
• PVT1 Knockdown Inhibits Autophagy and Improves Gemcitabine Sensitivity by Regulating the MiR-143/HIF-1α/VMP1 Axis in Pancreatic Cancer

  2021cited by this paper
• Deep-learning and MR images to target hypoxic habitats with evofosfamide in preclinical models of sarcoma

  2021cited by this paper
• Hypoxia promotes the metastasis of pancreatic cancer through regulating NOX4/KDM5A-mediated histone methylation modification changes in a HIF1A-independent manner

  2021cited by this paper
• High expression of hypoxia-inducible factor 1-alpha predicts poor prognosis in pancreatic ductal adenocarcinoma: a meta-analysis and database validation protocol

  2021cited by this paper
• Hypoxia responsive nano-drug delivery system based on angelica polysaccharide for liver cancer therapy

  2021cited by this paper
• A tumor microenvironment-responsive poly(amidoamine) dendrimer nanoplatform for hypoxia-responsive chemo/chemodynamic therapy

  2021cited by this paper
• A Review of the Role of Hypoxia in Radioresistance in Cancer Therapy

  2021cited by this paper
• The Extracellular Matrix in Pancreatic Cancer: Description of a Complex Network and Promising Therapeutic Options

  2021cited by this paper
• Vascular Normalization: A New Window Opened for Cancer Therapies

  2021cited by this paper
• Targeting Hypoxia: Hypoxia-Activated Prodrugs in Cancer Therapy

  2021influential reference
• Recent Advances in Tumor Targeting via EPR Effect for Cancer Treatment

  2021cited by this paper
• Targeting hypoxic tumor microenvironment in pancreatic cancer

  2021cited by this paper
• Suppression of pancreatic cancer liver metastasis by secretion-deficient ITIH5

  2020cited by this paper
• Pancreatic ductal adenocarcinoma: Treatment hurdles, tumor microenvironment and immunotherapy

  2020cited by this paper
• Hypoxia-induced epithelial to mesenchymal transition in cancer.

  2020cited by this paper
• Nanotechnology as a Platform for the Development of Injectable Parenteral Formulations: A Comprehensive Review of the Know-Hows and State of the Art

  2020influential reference
• Targeting the tumor core: hypoxia-responsive nanoparticles for delivery of chemotherapy to pancreatic tumors.

  2020cited by this paper
• Aptamers: a novel targeted theranostic platform for pancreatic ductal adenocarcinoma

  2020cited by this paper
• Hypoxia: Friend or Foe for drug delivery in Pancreatic Cancer.

  2020influential reference
• Clinical and Pre-Clinical Evidence of Carbonic Anhydrase IX in Pancreatic Cancer and Its High Expression in Pre-Cancerous Lesions

  2020cited by this paper
• Application and development of aptamer in cancer: from clinical diagnosis to cancer therapy

  2020cited by this paper
• Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma

  2020cited by this paper
• Aptamer-Functionalized Nanoparticles in Targeted Delivery and Cancer Therapy

  2020cited by this paper
• The phenotype of target pancreatic cancer cells influences cell death by magnetic hyperthermia with nanoparticles carrying gemicitabine and the pseudo-peptide NucAnt.

  2019cited by this paper
• Inhibition of HSP90 overcomes resistance to chemotherapy and radiotherapy in pancreatic cancer

  2019cited by this paper
• Hypoxic Radioresistance: Can ROS Be the Key to Overcome It?

  2019cited by this paper
• Nitroimidazole derivative incorporated liposomes for hypoxia-triggered drug delivery and enhanced therapeutic efficacy in patient-derived tumor xenografts.

  2019cited by this paper
• Hypoxia-responsive nanoparticle based drug delivery systems in cancer therapy: An up-to-date review.

  2019cited by this paper
• A Hypoxia‐Responsive Albumin‐Based Nanosystem for Deep Tumor Penetration and Excellent Therapeutic Efficacy

  2019cited by this paper
• Tumor-stromal crosstalk in pancreatic cancer and tissue fibrosis

  2019cited by this paper
• Smart nanomedicine agents for cancer, triggered by pH, glutathione, H2O2, or H2S

  2019cited by this paper
• Epithelial-Mesenchymal Plasticity in Cancer Progression and Metastasis.

  2019cited by this paper
• Role of hypoxia in cancer therapy by regulating the tumor microenvironment

  2019cited by this paper
• Stromal barriers to nanomedicine penetration in the pancreatic tumor microenvironment

  2018cited by this paper
• Light-enhanced hypoxia-responsive nanoparticles for deep tumor penetration and combined chemo-photodynamic therapy.

  2018cited by this paper
• Synthesis of New Branched 2-Nitroimidazole as a Hypoxia Sensitive Linker for Ligand-Targeted Drugs of Paclitaxel

  2018cited by this paper
• Molecular Transformer: A Model for Uncertainty-Calibrated Chemical Reaction Prediction

  2018cited by this paper
• CAIX aptamer-functionalized targeted nanobubbles for ultrasound molecular imaging of various tumors

  2018cited by this paper
• Dose escalation for locally advanced pancreatic cancer: How high can we go?

  2018influential reference
• Tissue-Penetrating, Hypoxia-Responsive Echogenic Polymersomes For Drug Delivery To Solid Tumors.

  2018cited by this paper
• Hypoxia-targeted gold nanorods for cancer photothermal therapy

  2018influential reference
• Hypoxia-Responsive Mesoporous Nanoparticles for Doxorubicin Delivery

  2018cited by this paper
• Use of Angiotensin System Inhibitors Is Associated with Immune Activation and Longer Survival in Nonmetastatic Pancreatic Ductal Adenocarcinoma

  2017cited by this paper
• Synthesis and Biological Evaluation of Paclitaxel and Camptothecin Prodrugs on the Basis of 2-Nitroimidazole.

  2017cited by this paper
• Molecular mechanisms of hypoxia in cancer

  2017cited by this paper
• Past, Present, and Future: Development of Theranostic Agents Targeting Carbonic Anhydrase IX

  2017cited by this paper
• Effect of FOLFIRINOX as second-line chemotherapy for metastatic pancreatic cancer after gemcitabine-based chemotherapy failure

  2017cited by this paper
• Barcoded nanoparticles for high throughput in vivo discovery of targeted therapeutics

  2017cited by this paper
• Targeting hypoxic microenvironment of pancreatic xenografts with the hypoxia-activated prodrug TH-302

  2016cited by this paper
• MAESTRO: A randomized, double-blind phase III study of evofosfamide (Evo) in combination with gemcitabine (Gem) in previously untreated patients (pts) with metastatic or locally advanced unresectable pancreatic ductal adenocarcinoma (PDAC).

  2016influential reference

• No citing papers are available for this paper.